BioSpace News Archive

Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases, announced topline results from a 12-week, randomized, placebo-controlled study of MET409 in patients with non-alcoholic steatohepatitis (NASH).

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2020, at 4:30 p.m. EST to discuss its financial results for the fiscal first quarter ended December 31, 2019.

Beyond Air, Inc. announced it will report financial results for its third fiscal quarter ended December 31, 2019 before the market open on Friday, February 7, 2020 and will host a conference call and webcast on at 11:00 am Eastern Time the same day.

Aruvant, a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for the treatment of severe blood disorders, today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to ARU-1801, Aruvant’s investigational therapy for the treatment of sickle cell disease.

Vizuri Health Sciences LLC reports that the American College of Rheumatology, an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.

Soin Neuroscience, a biotechnology company based in Dayton, OH, has developed a new spinal cord stimulation device to treat chronic pain.

PharmaMar and Jazz signed an exclusive license agreement on 19 December 2019 for lurbinectedin in the United States

Paper published in “Cytotherapy” to propose framework for critical standardization of ATMP material regulation

Technavio has announced its latest market research report titled global blister packaging machinery market 2020-2024.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, today announced that it received 510(k) clearance from the U.S. Food and Drug Administration for the WattsonTM Temporary Pacing Guidewire – the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV).